|
Journal of Lipid Research, Vol. 42, 1727-1739, November 2001
Copyright © 2001 by Lipid Research, Inc.
Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein
Francisco Blanco-Vacaa,b,
Joan Carles Escolà-Gila,b,
Jesús M. Martín-Camposa,b, and
Josep Julvea,c
a Servei de Bioquímica de l'Hospital de la Santa Creu i Sant Pau, Antoni M. Claret 167, 08025 Barcelona, Spain
b Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
c Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
Correspondence to:
Francisco Blanco-Vaca, To whom correspondence should be addressed., fblancova{at}hsp.santpau.es (E-mail)
Our understanding of apolipoprotein A-II (apoA-II) physiology is much more limited than that of apoA-I. However, important and rather surprising advances have been produced, mainly through analysis of genetically modified mice. These results reveal a positive association of apoA-II with FFA and VLDL triglyceride plasma concentrations; however, whether this is due to increased VLDL synthesis or to decreased VLDL catabolism remains a matter of controversy. As apoA-II-deficient mice present a phenotype of insulin hypersensitivity, a function of apoA-II in regulating FFA metabolism seems likely. Studies of human beings have shown the apoA-II locus to be a determinant of FFA plasma levels, and several genome-wide searches of different populations with type 2 diabetes have found linkage to an apoA-II intragenic marker, making apoA-II an attractive candidate gene for this disease. The increased concentration of apoB-containing lipoproteins present in apoA-II transgenic mice explains, in part, why these animals present increased atherosclerosis susceptibility. In addition, apoA-II transgenic mice also present impairment of two major HDL antiatherogenic functions: reverse cholesterol transport and protection of LDL oxidative modification. The apoA-II locus has also been suggested as an important genetic determinant of HDL cholesterol concentration, even though there is a major species-specific difference between the effects of mouse and human apoA-II. As antagonizing apoA-I antiatherogenic actions can hardly be considered the apoA-II function in HDL, this remains a topic for future investigations.
We suggest that the existence of apoA-II or apoA-I in HDL could be an important signal for specific interaction with HDL receptors such as cubilin or heat shock protein 60. Blanco-Vaca, F., J. C. Escolà-Gil, J. M. Martín-Campos, and J. Julve. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res. 2001. 42: 17271739.
Supplementary key words:
apoA-I, apoB, HDL, hyperlipidemia, hypertriglyceridemia, insulin resistance, triglycerides, type 2 diabetes, VLDL

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. E. Brousseau, J. S. Millar, M. R. Diffenderfer, C. Nartsupha, B. F. Asztalos, M. L. Wolfe, J. P. Mancuso, A. G. Digenio, D. J. Rader, and E. J. Schaefer
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism
J. Lipid Res.,
July 1, 2009;
50(7):
1456 - 1462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Su, X. Wang, S.-W. Tsaih, A. Zhang, A. Cox, S. Sheehan, and B. Paigen
Genetic basis of HDL variation in 129/SvImJ and C57BL/6J mice: importance of testing candidate genes in targeted mutant mice
J. Lipid Res.,
January 1, 2009;
50(1):
116 - 125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Thompson, J. F.P. Berbee, P. C.N. Rensen, and R. L. Kitchens
Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein
Innate Immunity,
December 1, 2008;
14(6):
365 - 374.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Scanu and C. Edelstein
HDL: bridging past and present with a look at the future
FASEB J,
December 1, 2008;
22(12):
4044 - 4054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. D. Wool, C. A. Reardon, and G. S. Getz
Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties
J. Lipid Res.,
June 1, 2008;
49(6):
1268 - 1283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Corella, D. K. Arnett, M. Y. Tsai, E. K. Kabagambe, J. M. Peacock, J. E. Hixson, R. J. Straka, M. Province, C.-Q. Lai, L. D. Parnell, et al.
The -256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network Study
Clin. Chem.,
June 1, 2007;
53(6):
1144 - 1152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Hime, K. J. Drew, K. Wee, P. J. Barter, and K.-A. Rye
Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit
J. Lipid Res.,
January 1, 2006;
47(1):
115 - 122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rodenas, S. Rodriguez-Gil, M. C. Merinero, and F. J. Sanchez-Muniz
Dietary Exchange of an Olive Oil and Sunflower Oil Blend for Extra Virgin Olive Oil Decreases the Estimate Cardiovascular Risk and LDL and Apolipoprotein AII Concentrations in Postmenopausal Women
J. Am. Coll. Nutr.,
October 1, 2005;
24(5):
361 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Rotllan, V. Ribas, L. Calpe-Berdiel, J. M. Martin-Campos, F. Blanco-Vaca, and J. C. Escola-Gil
Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2005;
25(9):
e128 - e132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang and B. Paigen
Genetics of Variation in HDL Cholesterol in Humans and Mice
Circ. Res.,
January 7, 2005;
96(1):
27 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Castellani, P. Gargalovic, M. Febbraio, S. Charugundla, M.-L. Jien, and A. J. Lusis
Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II
J. Lipid Res.,
December 1, 2004;
45(12):
2377 - 2387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Ribas, J. L. Sanchez-Quesada, R. Anton, M. Camacho, J. Julve, J. C. Escola-Gil, L. Vila, J. Ordonez-Llanos, and F. Blanco-Vaca
Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties: A New Mechanism Linking HDL Protein Composition and Antiatherogenic Potential
Circ. Res.,
October 15, 2004;
95(8):
789 - 797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang, R. Korstanje, D. Higgins, and B. Paigen
Haplotype Analysis in Multiple Crosses to Identify a QTL Gene
Genome Res.,
September 1, 2004;
14(9):
1767 - 1772.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Motizuki, T. Takei, K. Tasaka, S. Yokota, S. Kojima, T. Haga, and K. Tsurugi
Low pH Facilitates Uptake of Proteins by Cells through a Non-Endocytic Pathway
J. Biochem.,
June 1, 2004;
135(6):
713 - 719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. de Beer, L. W. Castellani, L. Cai, A. J. Stromberg, F. C. de Beer, and D. R. van der Westhuyzen
ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36
J. Lipid Res.,
April 1, 2004;
45(4):
706 - 715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sauvaget, V. Chauffeton, S. Dugue-Pujol, A.-D. Kalopissis, I. Guillet-Deniau, F. Foufelle, J. Chambaz, A. Leturque, P. Cardot, and A. Ribeiro
In Vitro Transcriptional Induction of the Human Apolipoprotein A-II Gene by Glucose
Diabetes,
March 1, 2004;
53(3):
672 - 678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lotharius and P. Brundin
Impaired dopamine storage resulting from {alpha}-synuclein mutations may contribute to the pathogenesis of Parkinson's disease
Hum. Mol. Genet.,
October 1, 2002;
11(20):
2395 - 2407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Julve, J. C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J. L. Sanchez-Quesada, and F. Blanco-Vaca
Mechanisms of HDL deficiency in mice overexpressing human apoA-II
J. Lipid Res.,
October 1, 2002;
43(10):
1734 - 1742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Julve, F. Blanco-Vaca, J. Carles Escola-Gil, F. M. van't Hooft, G. Ruotolo, S. Boquist, U. de Faire, G. Eggertsen, and A. Hamsten
On the Mechanisms by Which Human Apolipoprotein A-II Gene Variability Relates to Hypertriglyceridemia * Response
Circulation,
April 30, 2002;
105
(17):
e129 - e129.
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|